Although UCLA had. established policies and procedures for visiting ph
armaceutical representatives, changes in both the pharmaceutical busin
ess environment and in UCLA's physical environment mandated an update.
To deal with the changes, a multidisciplinary team comprised of vario
us departmental staff members met to develop a new vendor representati
ve visitation policy that included the practice of drug sample distrib
ution. More stringent registration requirements and shared responsibil
ity for policy enforcement are the key elements of the new policy.